X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (284) 284
Publication (46) 46
Patent (30) 30
Book Review (4) 4
Web Resource (4) 4
Book / eBook (2) 2
Conference Proceeding (2) 2
Technical Report (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (141) 141
oncology (121) 121
index medicus (106) 106
lung neoplasms - drug therapy (83) 83
carcinoma, non-small-cell lung - drug therapy (74) 74
female (73) 73
aged (69) 69
male (69) 69
middle aged (64) 64
chemotherapy (59) 59
lung neoplasms - genetics (57) 57
lung neoplasms - pathology (57) 57
mutation (54) 54
lung cancer (52) 52
antineoplastic agents - therapeutic use (50) 50
adult (49) 49
carcinoma, non-small-cell lung - genetics (49) 49
carcinoma, non-small-cell lung - pathology (44) 44
gefitinib (42) 42
receptor, epidermal growth factor - genetics (42) 42
cancer (39) 39
egfr (37) 37
lung cancer, non-small cell (37) 37
erlotinib (36) 36
respiratory system (36) 36
protein kinase inhibitors - therapeutic use (34) 34
non-small cell lung cancer (33) 33
aged, 80 and over (32) 32
open-label (31) 31
beer (30) 30
biochemistry (30) 30
chemistry (30) 30
compositions or test papers therefor (30) 30
condition-responsive control in microbiological orenzymological processes (30) 30
enzymology (30) 30
measuring or testing processes involving enzymes, nucleicacids or microorganisms (30) 30
metallurgy (30) 30
microbiology (30) 30
mutation or genetic engineering (30) 30
processes of preparing such compositions (30) 30
spirits (30) 30
vinegar (30) 30
wine (30) 30
quinazolines - therapeutic use (29) 29
prognosis (28) 28
research (28) 28
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
care and treatment (27) 27
treatment outcome (27) 27
tyrosine kinase inhibitors (26) 26
nsclc (25) 25
receptor, epidermal growth factor - antagonists & inhibitors (25) 25
acquired-resistance (24) 24
hematology, oncology and palliative medicine (23) 23
neoplasm staging (23) 23
1st-line treatment (22) 22
growth-factor receptor (22) 22
cell lung-cancer (21) 21
lung neoplasms - metabolism (21) 21
metastasis (21) 21
phase-iii trial (21) 21
gene copy number (20) 20
survival (20) 20
analysis (19) 19
animals (19) 19
antineoplastic agents - pharmacology (19) 19
cetuximab (19) 19
disease progression (19) 19
drug resistance, neoplasm (19) 19
therapy (19) 19
tumors (19) 19
tyrosine kinase inhibitor (19) 19
carcinoma, non-small-cell lung - metabolism (18) 18
carcinoma, non-small-cell lung - mortality (18) 18
derivatives thereof (18) 18
disease-free survival (18) 18
epidermal growth factor (18) 18
lung neoplasms - mortality (18) 18
nucleic acids (18) 18
nucleosides (18) 18
nucleotides (18) 18
organic chemistry (18) 18
sugars (18) 18
adenocarcinoma (17) 17
egfr mutations (17) 17
growth-factor-receptor (17) 17
in situ hybridization, fluorescence (17) 17
survival analysis (17) 17
clinical trials as topic (16) 16
docetaxel (16) 16
expression (16) 16
non-small-cell lung cancer (16) 16
patients (16) 16
pulmonary/respiratory (16) 16
clinical trials (15) 15
drug therapy (15) 15
pharmacology & pharmacy (15) 15
receptor, epidermal growth factor - metabolism (15) 15
respiratory tract diseases (15) 15
genetic aspects (14) 14
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 8, pp. 753 - 762
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9944, pp. 665 - 673
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 257 - 265
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 6, pp. 521 - 529
Journal Article
2015, 1st ed. 2015., ISBN 3319207415
This text is a concise and up-to-date review, which discusses the background, development and mechanisms of resistance, testing methods and technology, current... 
Medicine | Oncology
Web Resource
2015, 1st ed. 2015., ISBN 3319207415
This text is a concise and up-to-date review, which discusses the background, development and mechanisms of resistance, testing methods and technology, current... 
Medicine | Oncology
Web Resource
Annals of Oncology, ISSN 0923-7534, 2/2009, Volume 20, Issue 2, pp. 298 - 304
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 06/2018, Volume 24, Issue 11, pp. 2470 - 2472
HER2-deregulated non-small cell lung cancer is an orphan of any specific therapy, probably because of lack of both accurate patient selection and effective... 
RESISTANCE | ONCOLOGY | GEFITINIB THERAPY | GENE COPY NUMBER | MUTATION | Acrylamides | Piperazines | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Aniline Compounds | Humans | Deregulation | ErbB-2 protein | Lung cancer | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 24, pp. 2288 - 2301
The addition of atezolizumab (anti–PD-L1 antibody) to a platinum-based chemotherapy regimen improved progression-free survival among patients who had not... 
PHASE-III TRIAL | CELLS | MULTICENTER | THERAPY | BEVACIZUMAB | ANTIBODY | OPEN-LABEL | CANCER | DOCETAXEL | CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Neoplasm Metastasis - drug therapy | Immunotherapy | Female | Paclitaxel - administration & dosage | Bevacizumab - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Carboplatin - administration & dosage | Carcinoma, Non-Small-Cell Lung - mortality | Genes, erbB-1 | B7-H1 Antigen - antagonists & inhibitors | Receptor Protein-Tyrosine Kinases - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Lung cancer, Non-small cell | Drug therapy | Research | Epidermal growth factor receptors | Liver | Non-small cell lung carcinoma | Oncology | Lymphocytes T | Metastasis | Cancer therapies | Patients | Bevacizumab | Metastases | Immunosuppression | Chemotherapy | Motivation | Medical prognosis | PD-L1 protein | Paclitaxel | Carboplatin | Population | Death | Vascular endothelial growth factor | Genotypes | Apoptosis | Tumors
Journal Article
2014, ISBN 9783319030586
Guide to Targeted Therapies: EGFR Mutations in NSCLC is a speedy and up-to-date review, which discusses EGFR mutations, testing methods and technology, current... 
Medicine | Oncology | Pneumology
Web Resource
Lancet Oncology, The, ISSN 1470-2045, 2019, Volume 20, Issue 9, pp. e467 - e467
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Chemotherapy | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article